Grace Therapeutics, Inc. - Common Stock (GRCE)

2.1800
+0.0300 (1.40%)
NASDAQ· Last Trade: May 20th, 6:50 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Thursday's session: top gainers and loserschartmill.com
Via Chartmill · April 23, 2026
Which stocks are moving on Tuesday?chartmill.com
Via Chartmill · April 7, 2026
Gapping stocks in Tuesday's sessionchartmill.com
Via Chartmill · April 7, 2026
Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Studybenzinga.com
Grace Therapeutics' GTx-104 met its Phase 3 trial endpoint, showing clinical benefits over oral nimodipine. US NDA submission is expected in early 2025.
Via Benzinga · February 10, 2025